This may be somewhat old news, but I just ran across an article at nyt.com about a company in India that is starting to produce the the Oxford vaccine, gambling that it will prove to be effective. What's interesting is that this is apparenlty all private equity, at least so far:
>>>The Serum Institute, which is exclusively controlled by a small and fabulously rich Indian family and started out years ago as a horse farm, is doing what a few other companies in the race for a vaccine are doing: mass-producing hundreds of millions of doses of a vaccine candidate that is still in trials and might not even work.
But if it does, Adar Poonawalla, Serum’s chief executive and the only child of the company’s founder, will become one of the most tugged-at men in the world. He will have on hand what everyone wants, possibly in greater quantities before anyone else.
His company, which has teamed up with the Oxford scientists developing the vaccine,
was one of the first to boldly announce, in April, that it was going to mass-produce a vaccine before clinical trials even ended. Now, Mr. Poonawalla’s fastest vaccine assembly lines are being readied to crank out 500 doses each minute, and his phone rings endlessly. . . .
AstraZeneca is the lead partner with the Oxford scientists, and it has signed government contracts worth more than $1 billion to manufacture the vaccine for Europe, the United States and other markets. But it has allowed the Serum Institute to produce it as well. The difference, Mr. Poonawalla said, is that his company is shouldering the cost of production on its own.
But Serum is distinct from all other major vaccine producers in an important way. Like many highly successful Indian businesses, it is family-run. It can make decisions quickly and take big risks, like the one it’s about to, which could cost the family hundreds of millions of dollars.
Mr. Poonawalla said he was “70 to 80 percent” sure the Oxford vaccine would work. . . .
But even if this vaccine fails to win the race, the Serum Institute will still be instrumental. It has teamed up with other vaccine designers, at earlier stages of development, to manufacture four other vaccines, though those are not being mass produced yet.
And if all of those fail, Mr. Poonawalla says he can quickly adapt his assembly lines to manufacture whatever vaccine candidate does work, wherever it comes from.
“Very few people can produce it at this cost, this scale and this speed,” he said.<<<
The world’s largest vaccine producer, the Serum Institute, announced a plan to make hundreds of millions of doses of an unproven inoculation. It’s a gamble with a huge upside. And huge risks.
www.nytimes.com